The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rynda A.Yu.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

Olyushin V.E.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

Rostovtsev D.M.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

Zabrodskaya Yu.M.

Prof. A.L. Polenov Russian Research Institute of Neurosurgery — Branch V.A. Almazov National Medical Research Center of the Ministry of Health of Russia

Complex treatment of a patient with neurofibromatosis type 2

Authors:

Rynda A.Yu., Olyushin V.E., Rostovtsev D.M., Zabrodskaya Yu.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8): 98‑104

DOI: 10.17116/jnevro202012008198

Read: 17511 times

Download PDF (RU)
Contact the author
Table of contents

COMPLEX TREATMENT OF A PATIENT WITH NEUROFIBROMATOSIS TYPE 2
COMPLEX TREATMENT OF A PATIENT WITH NEUROFIBROMATOSIS TYPE 2

To cite this article:

Rynda AYu, Olyushin VE, Rostovtsev DM, Zabrodskaya YuM. Complex treatment of a patient with neurofibromatosis type 2. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):98‑104. (In Russ.)
https://doi.org/10.17116/jnevro202012008198

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modern methods of diagnosis and endo­scopic treatment Zenker’s dive­rticulum. Endo­scopic Surgery. 2025;(3):36-43
Analysis of the resu­lts of treatment of a patient with a facial nerve tumor. Russian Bulletin of Otorhinolaryngology. 2025;(3):88-92
Post-radiation choroidal mela­noma pathomorphosis asse­ssment in clinical practice. Russian Journal of Archive of Pathology. 2025;(3):33-39
Arti­ficial inte­lligence in surgery. Redu­cing the risks rela­ted to poly­pharmacy in perioperative period. Piro­gov Russian Journal of Surgery. 2025;(7):59-66
Anti­reflex endo­tracheal tube in clinical practice. Russian Journal of Anesthesiology and Reanimatology. 2025;(4):54-60
Thyroid mini-access on the ante­rior surface of the neck (anatomo-clinical study). Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(3):29-40
Machine learning models for brain tumors differential diagnosis. Russian Journal of Preventive Medi­cine. 2025;(9):87-93
Surgical treatment of glial tumors of the frontal lobe. Current state of the problem. Part I: motor functional system. Burdenko's Journal of Neurosurgery. 2025;(5):115-121
Beautiful rela­tionship between art and medi­cine: from clay mode­ling to auri­cular cartilage mode­ling. Plastic Surgery and Aesthetic Medi­cine. 2025;(3-2):71-77
Surgical treatment of intracerebral frontal lobe tumors. Part II: speech functional system. Burdenko's Journal of Neurosurgery. 2025;(6):114-119
Abstract:

Neurofibromatosis type 2, a rare disease, the most characteristic manifestation of which is the presence of bilateral vestibular schwannomas, less often schwannomas of other cranial, spinal and peripheral nerves. Much less frequent are meningiomas (intracranial, including meningiomas of the optic nerves, and spinal), epindymomas and gliomas. As a rule, in one patient several formations occur simultaneously, which creates a certain difficulty in treatment tactics. The authors present a case of type 2 neurofibromatosis in a 22-year-old female patient with multiple schwannomas of spinal roots and an atypical intraventricular meningioma.

Keywords:

neurofibromatosis 2 type
surgery
gamma knife
neuro-oncology
meningiomas
schwannomas

Authors:

Rynda A.Yu.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

Olyushin V.E.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

Rostovtsev D.M.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

Zabrodskaya Yu.M.

Prof. A.L. Polenov Russian Research Institute of Neurosurgery — Branch V.A. Almazov National Medical Research Center of the Ministry of Health of Russia

Received:

22.09.2019

Accepted:

24.03.2020

Close metadata

References:

  1. Ruggieri M, Praticò AD, Caltabiano R, Polizzi A. Early history of the different forms of neurofibromatosis from ancient Egypt to the British Empire and beyond: first descriptions, medical curiosities, misconceptions, landmarks, and the persons behind the syndromes. American Journal of Medical Genetics Part A. 2018;176(3):515-550.  https://doi.org/10.1002/ajmg.a.38486
  2. Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Druker H, Scott HS, Tabori U. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clinical Cancer Research. 2017;23(12):54-61. 
  3. Goutagny S, Bah AB, Parfait B, Sterkers O, Kalamarides M. Neurofibromatosis type 2 in the elderly population: clinical and molecular features. American Journal of Medical Genetics Part A. 2013;161A(4):667-670. 
  4. Pashchenko MS, Karandasheva KO, Kuznetsova EB, Anisimova IV, Bessonova LA, Galkina VA, Guseva DM, Demina NA, Makienko ON, Markova TV, Matyushchenko GN, Petukhova MS, Semenova NA, Tanas AS, Zaletaev DV, Strelnikov VV. Genetic analysis of 617 Russian neurofibromatosis patients: novel pathogenic and rare non-pathogenic mutations. Medical Genetics. 2018;17(11):20-24. (In Russ.)
  5. Castellanos E, Plana A, Carrato C, Carrió M, Rosas I, Amilibia E, Roca-Ribas F, Hostalot C, Castillo A, Ros A, Quer A, Becerra JL, Salvador H, Lázaro C, Blanco I, Serra E, Bielsa I. Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood. JAMA Dermatology. 2018;154(3):341-346.  https://doi.org/10.1001/jamadermatol.2017.5464
  6. Dewan R, Pemov A, Dutra AS, Pak ED, Edwards NA, Ray-Chaudhury A, Hansen NF, Chandrasekharappa SC, Mullikin JC, Asthagiri AR, Heiss JD, Stewart DR, Germanwala AV. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. BMC Cancer. 2017;17(1):127.  https://doi.org/10.1186/s12885-017-3127-6
  7. Pathmanaban ON, Sadler KV, Kamaly-Asl ID, King AT, Rutherford SA, Hammerbeck-Ward C, McCabe MG, Kilday JP, Beetz C, Poplawski NK, Evans DG, Smith MJ. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurology. 2017;74(9):1123-1129. https://doi.org/10.1001/jamaneurol.2017.1406
  8. Truong K, Ahmad I, Jason Clark J, Seline A, Bertroche T, Mostaert B, Van Daele DJ, Hansen MR. Nf2 mutation in schwann cells delays functional neural recovery following injury. Neuroscience. 2018;15(374):205-213.  https://doi.org/10.1016/j.neuroscience.2018.01.054
  9. Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A, O’Malley J, Whitfield GA, McCabe MG, Freeman SR, Lloyd SK, Wright NB, Kilday JP, Kamaly-Asl ID, Mills SJ, Rutherford SA, King AT, Evans DG. Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. Journal of Medical Genetics. 2015;52(8):557-562.  https://doi.org/10.1136/jmedgenet-2015-103050
  10. Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, Lloyd SK, Rutherford SA, Hammerbeck-Ward CL, Freeman SR, Evans DG. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88(1):87-92.  https://doi.org/10.1212/WNL.0000000000003418
  11. Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, Evans DG, Parry A. Genetic severity Score predicts clinical phenotype in NF2. Journal Med Genet. 2017;54(10):657-664.  https://doi.org/10.1136/jmedgenet-2017-104519
  12. Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT, Friedman JM, Evans DG. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics. 2015;52(10):699-705.  https://doi.org/10.1136/jmedgenet-2015-103290
  13. Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveal differences in efficacy and drug resistance development. Neuro Oncology. 2019;21(4):486-497.  https://doi.org/10.1093/neuonc/noz002
  14. Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R, Lloyd SKL, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Stapleton E, Freeman SR, Kellett M, Halliday D, Parry A, Gair JJ, Axon P, Laitt R, Thomas O, Afridi S, Ferner RE, Harkness EF, Smith MJ. Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. 2019;21(7):1525-1533. https://doi.org/10.1038/s41436-018-0384-y
  15. Evans DG, Freeman S, Gokhale C, Wallace A, Lloyd SK, Axon P, Ward CL, Rutherford S, King A, Huson SM, Ramsden RT. Bilateral vestibular schwannomas in older patients: NF2 or chance? Journal of Medical Genetics. 2015;52(6):422-424.  https://doi.org/10.1136/jmedgenet-2014-102973
  16. Asthagiri AR, Vasquez RA, Butman JA, Wu T, Morgan K, Brewer CC, King K, Zalewski C, Kim HJ, Lonser RR. Mechanism of hearing loss in neurofibromatosis type 2. PLoS One. 2012;7(9):e46132. https://doi.org/10.1371/journal.pone.0046132
  17. Kalamarides M, Essayed W, Lejeune JP, Aboukais R, Sterkers O, Bernardeschi D, Peyre M, Lloyd SK, Freeman S, Hammerbeck-Ward CL, Kellett M, Rutherford SA, Evans DG, Pathmanaban O, King A. Spinal ependymomas in NF2: a surgical disease? Journal Neurooncology. 2018;136(3):605-611.  https://doi.org/10.1007/s11060-017-2690-7
  18. Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncology. 2018;20(9):1185-1196. https://doi.org/10.1093/neuonc/noy046
  19. King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON, Rodriguez-Valero M, Thomas OM, Laitt RD, Stivaros S, Kellett M, Evans DG. High-grade glioma is not a feature of neurofibromatosis type 2 in the unirradiated patient. Neurosurgery. 2018;83(2):193-196.  https://doi.org/10.1093/neuros/nyx374
  20. King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON. Malignant peripheral nerve sheath tumors are not a feature of neurofibromatosis type 2 in the unirradiated patient. Neurosurgery. 2018;83(1):38-42.  https://doi.org/10.1093/neuros/nyx368
  21. Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. Journal Clinical Oncology. 2016;34(14):1669-1175. https://doi.org/10.1200/JCO.2015.64.3817
  22. Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proceedings of the National Academy of Sciences USA. 2015; 112(47):14676-14681. https://doi.org/10.1073/pnas.1512570112
  23. Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018;13(6):e0197350. https://doi.org/10.1371/journal.pone.0197350
  24. Montgomery BK, Alimchandani M, Mehta GU, Dewan R, Nesvick CL, Miettinen M, Heiss JD, Asthagiri AR, Quezado M, Germanwala AV. Tumors displaying hybrid schwannoma and neurofibroma features in patients with neurofibromatosis type 2. Clinical Neuropathology. 2016;35(2):78-83.  https://doi.org/10.5414/np300895
  25. Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proceedings of the National Academy of Sciences USA. 2018;115(9):2077-2084. https://doi.org/10.1073/pnas.1719966115
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.